首页> 美国卫生研究院文献>other >Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

【2h】

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

机译：贝伐单抗联合修饰的FOLFOX6在HER2 / Neu阴性转移性乳腺癌大量预处理患者中的II期临床试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundBevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer. The present study was to determine the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2eu)-negative MBC.

机译：背景贝伐单抗联合修饰的FOLFOX6是结直肠癌的标准治疗方案。本研究旨在确定贝伐单抗修饰的FOLFOX6方案在人表皮生长因子受体2（HER2 / neu）阴性MBC进行大量预处理的患者中的疗效和安全性。

著录项

期刊名称 other
作者
Ting Li; Biyun Wang; Zhonghua Wang; Joseph Ragaz; Jian Zhang; Si Sun; Jun Cao; Fangfang Lv; Leiping Wang; Sheng Zhang; Chen Ni; Zhenhua Wu; Jie Xie; Xichun Hu;
展开▼
作者单位

展开▼
年(卷),期 -1(10),7
年度 -1
页码 e0133133
总页数 14
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：多中心期II研究评估Nivolumab Plus Paclitaxel Plus Bevacizumab三重组合疗法作为Her2阴性转移乳腺癌患者的一线治疗的疗效：WJOG9917B Newbeat试验
2. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer [J] . Dimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis, BMC Cancer . 2015 ,第1期

机译：Ⅲ期随机临床试验比较了卡培他滨和奥沙利铂（CAPOX）联合5-氟尿嘧啶，亚叶酸和奥沙利铂（改良的FOLFOX6）联合治疗高危II期或III期大肠癌患者的辅助治疗
3. Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA [J] . Anjie Zhu, Fei Ma, Pin Zhang, 癌症生物学与医学（英文版） . 2021 ,第003期

机译：Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer [O] . Dimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis, 2015

机译：III期临床试验比较卡培他滨与奥沙利铂（CAPOX）组合与5-氟尿嘧啶亚叶酸和奥沙利铂（改良的FOLFOX6）组合作为辅助治疗手术后高危II期或III期结直肠癌患者的临床试验
7. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. [O] . Ting Li, Biyun Wang, Zhonghua Wang, 2015

机译：Bevacizumab联合改良FOLFOX6治疗重度预处理的HER2 / Neu阴性转移性乳腺癌患者：II期临床试验。

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

摘要

著录项

相似文献

相关主题

期刊订阅